6 results about "Tissue factor pathway inhibitor" patented technology

Described herein are compositions and kits comprising recombinant adeno-associated viruses (rAAVs) with increased transduction enrichment in the central nervous system, brain, and / or spinal cord. The rAAV compositions described herein encapsidate a transgene, such as a therapeutic nucleic acid. The rAAV capsid and capsid proteins described herein comprise a sequence that bind to the TEK receptor tyrosine kinase (TEK) protein and / or tissue factor pathway inhibitor (TFPI) protein to facilitate crossing the blood-brain barrier. Gene therapy using the rAAVs is described. Also described are methods of treating brain-, spinal-, and central nervous system-related diseases and conditions.

The present invention relates to antibodies and antigen-binding fragments thereof that specifically bind to TFPI and inhibit its activity. These antibodies and fragments can be used to treat hemorrhagic disorders and shorten the clotting time.

Current approaches in small diameter vascular grafts for coronary artery bypass surgeries fail to address physiological variations along the graft that contribute to thrombus formation and ultimately graft failure. An interlayer drug delivery system can sustain delivery of heparin through the graft with a high degree of temporal and spatial control. A heparin-loaded gelatin methacrylate interlayer sits between a biohybrid composed of decellularized bovine pericardium and poly(propylene fumarate) and UV crosslinking is controlled via 3D printed shadow masks. The masks enable control of the resultant gelMA crosslinking and properties by modulating the incident light intensity on the graft. High doses of heparin have detrimental effects on endothelial cell function. When exposed to heparin in a slower, more sustained manner consistent with the masks, endothelial cells behave similarly to untreated cells. Slower release profiles cause significantly more release of tissue factor pathway inhibitor, an anticoagulant, than a faster release profile.

The invention relates to fusion proteins comprising tissue factor pathway inhibitor alpha (TFPlα) or a functional fragment thereof and, an exogenous protein S binding moiety, especially complement component 4 binding protein beta (C4BPβ), or a functional fragment thereof. The invention further relates to compositions comprising the same, as well as uses thereof, in particular to inhibit coagulation or for treating thrombotic events, vectors encoding such fusion protein and, method of production thereof.

Antibodies and antigen-binding fragments thereof that specifically bind and inhibit the activity of TFPI are provided. Such antibodies and fragments are useful for treating bleeding disorders and shortening clotting times. The present invention provides an isolated antibody or antigen-binding fragment thereof that specifically binds to an epitope in Kunitz domain 2 (K2) of tissue factor pathway inhibitor (TFPI).

Disclosed is a monoclonal antibody or an antigen binding fragment thereof which targets tissue factor pathway inhibitor (TFPI), and a medical use thereof.